PTPI (Petros Pharmaceuticals) Net Margin %: 0.00% (As of Mar. 2026)


What is Petros Pharmaceuticals Net Margin %?

Petros Pharmaceuticals PTPI Net Margin % is 0.00% as of Mar. 2026. Among 956 Drug Manufacturers companies, Petros Pharmaceuticals ranks worse than 104602.41% on this metric.

Net margin is calculated as Net Income divided by its Revenue. Petros Pharmaceuticals's Net Income for the three months ended in Mar. 2026 was $-0.99 Mil. Petros Pharmaceuticals's Revenue for the three months ended in Mar. 2026 was $0.00 Mil. Therefore, Petros Pharmaceuticals's net margin for the quarter that ended in Mar. 2026 was 0.00%.

The historical rank and industry rank for Petros Pharmaceuticals's Net Margin % or its related term are showing as below:


PTPI's Net Margin % is not ranked *
in the Drug Manufacturers industry.
Industry Median: 5.56
* Ranked among companies with meaningful Net Margin % only.

Petros Pharmaceuticals  (OTCPK:PTPI) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.

Petros Pharmaceuticals Net Margin % Related Terms

Petros Pharmaceuticals Net Margin % Historical Data

* Premium members only.

The historical data trend for Petros Pharmaceuticals's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Petros Pharmaceuticals Net Margin % Chart

Petros Pharmaceuticals Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Net Margin %
Get a 7-Day Free Trial -115.06 -334.41 -140.21 0.00 0.00

Petros Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Net Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

PTPI vs GCAN, KOAN, PNXP: Net Margin % Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Petros Pharmaceuticals's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Petros Pharmaceuticals Net Margin % vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Petros Pharmaceuticals's Net Margin % distribution charts can be found below:

* The bar in red indicates where Petros Pharmaceuticals's Net Margin % falls into.


Petros Pharmaceuticals Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Petros Pharmaceuticals's Net Margin for the fiscal year that ended in Dec. 2025 is calculated as

Net Margin=Net Income (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=1.914/0
= %

Petros Pharmaceuticals's Net Margin for the quarter that ended in Mar. 2026 is calculated as

Net Margin=Net Income (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=-0.987/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Net Margin % →
What does a Net Margin % of 0.00% mean?
Petros Pharmaceuticals (PTPI) has a Net Margin % of 0.00% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Petros Pharmaceuticals and its competitors. According to the industry distribution chart, Petros Pharmaceuticals ranks #999999 out of 956 companies in the Drug Manufacturers industry.
Is Petros Pharmaceuticals' Net Margin % too high?
Petros Pharmaceuticals' current Net Margin % is 0.00%. Based on the distribution chart, Petros Pharmaceuticals ranks #999999 out of 956 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers.
How does Petros Pharmaceuticals' Net Margin % compare to GCAN and KOAN?
According to the Drug Manufacturers industry distribution chart, Petros Pharmaceuticals ranks #999999 out of 956 companies for Net Margin %. This places Petros Pharmaceuticals in the lower half of its industry. The industry median Net Margin % is 5.56. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Drug Manufacturers company?
The median Net Margin % among Drug Manufacturers companies is 5.56, based on 956 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Petros Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median Net Margin % is 5.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Petros Pharmaceuticals's current Net Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Petros Pharmaceuticals stock overvalued right now?
Petros Pharmaceuticals (PTPI) has a current Net Margin % of 0.00%. The current Net Margin % is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Petros Pharmaceuticals (PTPI), the current Net Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Petros Pharmaceuticals Business Description

Address 1185 Avenue of the Americas, 3rd Floor, New York, NY, USA, 10036
Petros Pharmaceuticals Inc is a men's health pharmaceutical company. The Company is working towards the goal of becoming an innovator in the emerging self-care market, driving expanded access to key nonprescription pharmaceuticals as Over-the-Counter and nonprescription drug products with additional conditions for nonprescription use (ACNU Products) treatment options. Petros is pursuing the development of a proprietary integrated technology solutions platform containing two components: SaaS, designed to assist pharmaceutical companies in operationalizing and commercializing an Rx-to-OTC switch as an element in the development of an ACNU Product, and a potential Software as a Medical Device component, which guides the consumer in navigating appropriate self-selection or deselection.